Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PRKCA | P17252 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117838 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2EPHX2HPGDHTTTLR2 | |
| SCHEMBL14985548 | 0.87 | USP2 (0.37) | SMN1; SMN2KMT2APRKCAMAPTALDH1A1 | |
| SCHEMBL12355355 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2EPHX2LMNAHPGDHTT | |
| SCHEMBL20934157 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2APRKCAMAPTGAA | |
| SCHEMBL13369011 | 0.84 | LPAR5 (0.37) | SMN1; SMN2KMT2APRKCAMAPTALDH1A1 | |
| SCHEMBL26186366 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AEPHX2PRKCAGAA | |
| SCHEMBL12201703 | 0.83 | MAPT (0.38) | SMN1; SMN2KMT2APRKCAMAPTALDH1A1 | |
| SCHEMBL28711763 | 0.82 | ALOX12 (0.36) | SMN1; SMN2KMT2AGAAHPGDHTT | |
| SCHEMBL828854 | 0.81 | TLR2 (0.41) | SMN1; SMN2KMT2AGAAALDH1A1LMNA | |
| SCHEMBL14401860 | 0.81 | LPAR6 (0.37) | SMN1; SMN2ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2017-10-05 | — | — | US | disclosed |
| US-20150258206-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK AS (DK) | 2015-09-17 | — | — | US | disclosed |
| US-8911967-B2 | One pot desialylation and glycopegylation of therapeutic peptides | NOVO NORDISK A/S (DK) | 2014-12-16 | — | — | US | disclosed |
| US-20130137157-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2013-05-30 | — | — | US | disclosed |
| US-8003117-B2 | Purity; polyether containing glycerol backbone capable of being label | NOF CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20100330645-A1 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20100113743-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100041872-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NOVO NORDISK A/S (DK) | 2010-02-18 | — | — | US | disclosed |
| US-20100009902-A1 | Glycoconjugation Using Saccharyl Fragments | NEOSE TECHNOLOGIES, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090305967-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2009-12-10 | — | — | US | disclosed |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305967-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | F7, F13B, F13A1 | SMN1; SMN2 3543/4885KMT2A 1649/4885EPHX2 749/4885 |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | SMN1; SMN2 4565/4885KMT2A 3984/4885EPHX2 2504/4885 |
| US-20100009902-A1 | Glycoconjugation Using Saccharyl Fragments | B3GAT3, UGGT1, UGCG | SMN1; SMN2 3800/4885KMT2A 1491/4885EPHX2 1013/4885 |
| US-20100113743-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | F7, F13B, F13A1 | SMN1; SMN2 3543/4885KMT2A 1649/4885EPHX2 749/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | SMN1; SMN2 3866/4885KMT2A 2346/4885EPHX2 2374/4885 |
| US-20100041872-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | SMN1; SMN2 4565/4885KMT2A 3984/4885EPHX2 2504/4885 |
| US-20170281785-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | SMN1; SMN2 4565/4885KMT2A 3984/4885EPHX2 2504/4885 |
| US-20150258206-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | SMN1; SMN2 4565/4885KMT2A 3984/4885EPHX2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.